XML 53 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements Of Cash Flows (USD $)
 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Cash Flows from Operating Activities:    
Net income $ 103,837,000 $ 98,865,000
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 28,089,000 27,357,000
Loss on disposal of property and equipment   71,000
Gain on sale of equity investment (697,000)  
Impairment of property and equipment 800,000  
Increase in deferred compensation liability 7,000 89,000
Provision for uncollectible accounts 788,000 780,000
Benefit of deferred income taxes (5,225,000) (1,256,000)
Share-based compensation expense 8,820,000 8,108,000
Tax benefit from share-based compensation arrangements (7,960,000) (5,830,000)
Changes in assets and liabilities:    
Accounts receivable (9,786,000) (24,161,000)
Inventories (5,575,000) (4,939,000)
Other assets (2,950,000) 4,407,000
Accounts payable 337,000 6,466,000
Accrued liabilities (3,344,000) (9,837,000)
Deferred revenue 8,139,000 2,364,000
Net cash provided by operating activities 115,280,000 102,484,000
Cash Flows from Investing Activities:    
Purchases of property and equipment (25,410,000) (46,181,000)
Proceeds from disposition of pharmaceutical product lines   3,500,000
Proceeds from sale of equity investment 5,400,000  
Acquisitions of intangible assets (175,000) (659,000)
Acquisition of businesses, net of cash acquired (1,161,000)  
Net cash used by investing activities (21,346,000) (43,340,000)
Cash Flows from Financing Activities:    
Borrowings on revolving credit facilities, net 107,000,000 155,500,000
Debt issue costs (1,156,000)  
Payment of notes payable (1,394,000) (480,000)
Repurchases of common stock (196,626,000) (206,335,000)
Proceeds from exercises of stock options and employee stock purchase plans 14,707,000 16,420,000
Tax benefit from share-based compensation arrangements 7,960,000 5,830,000
Net cash (used) provided by financing activities (69,509,000) (29,065,000)
Net effect of changes in exchange rates on cash 1,565,000 (3,052,000)
Net increase in cash and cash equivalents 25,990,000 27,027,000
Cash and cash equivalents at beginning of period 279,058,000 223,986,000
Cash and cash equivalents at end of period 305,048,000 251,013,000
Supplemental Disclosure of Non-Cash Information:    
Market value of common shares received from employees in connection with share-based compensation - see Note 18 $ 5,200,000 $ 4,300,000